Table 1.
Characteristics of all patients with proliferative diabetic retinopathy enrolled in the study according to follow-up status.
| Followed up | LTFU | All subjects | P value | |
|---|---|---|---|---|
| Number of eyes (%) | 391 (83.7%) | 76 (16.3%) | 467 | — |
| Baseline LogMAR BCVA (Snellen equivalent) | 0.22 ± 0.07 (20/33) | 0.26 ± 0.10 (20/36) | 0.23 ± .08 (20/34) | 0.001 |
| Age (yrs) | 57.11 ± 9.83 | 52.78 ± 8.25 | 56.40 ± 9.72 | 0.001 |
| Gender, n (%) | 0.93 | |||
| Male | 208 (83.9%) | 40 (16.1%) | 248 | |
| Female | 183 (83.6%) | 36 (16.4%) | 219 | |
| Age category (yrs), n (%) | 0.005 | |||
| ≤50 years | 89 (76.1%) | 28 (23.9%) | 117 | |
| 51–60 years | 166 (83.0%) | 34 (17.0%) | 200 | |
| ≥61 years | 136 (90.7%) | 14 (9.3%) | 150 | |
| Procedure, n (%) | 0.003 | |||
| IVI | 82 (91.1%) | 8 (8.9%) | 90 | |
| PRP | 157 (87.2%) | 23 (12.8%) | 180 | |
| IVI + PRP | 152 (77.2%) | 45 (22.8%) | 197 | |
| LogMAR BCVA at final follow-up (Snellen equivalent) | 0.31 ± 0.28 (20/40) | 0.47 ± 0.42 (20/59) | 0.43 ± 0.32(20/43) | 0.001 |
Data presented mean ± standard deviation and n (%) as applicable. For LTFU group, interventions represented were done before point of LTFU. BCVA = best corrected visual acuity, IVI = intravitreal injection, LogMAR = logarithm of the minimum angle resolution, LTFU = loss to follow-up, and PRP = panretinal photocoagulation.